Drug intelligence / Profile preview

garivulimab

Development stage: Discontinued
Lead developer: BeiGene
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous, Subcutaneous

Overview

Garivulimab is a monoclonal antibody drug. However, based on the available search results, there is no detailed information about its mechanism of action, developer, manufacturer, or clinical indications. The name "garivulimab" follows the standard World Health Organization International Nonproprietary Names (INN) convention for monoclonal antibodies (ending in -mab), indicating it is likely an investigational or less widely known antibody therapy. No evidence was found linking garivulimab to any approved indication or ongoing clinical development in major public databases as of May 2025.

Other names: garivulimab

Targets

CD274 (Programmed cell death protein 1 ligand 1)

Beyond the preview

Go deeper on garivulimab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on garivulimab.

Explore the full profile